3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Genomic Instability
1
Interventions
Paclitaxel
134
Carboplatin
129
Bevacizumab
86
Gemcitabine
45
pembrolizumab
37
olaparib
33
Cisplatin
30
liposomal doxorubicin
29
Docetaxel
29
Cyclophosphamide
29
Topotecan
28
niraparib
27
Taxes
20
Etoposide
18
Filgrastim
16
Doxorubicin
16
Immunoglobulin G
15
Disulfides
15
apatinib
12
Letrozole
12
Albumin-Bound Paclitaxel
12
Drug Therapy
11
fluzoparib
10
fludarabine
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
10
durvalumab
9
Nivolumab
9
pazopanib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts